CSIMarket Company Name, Ticker, Competitors, else..


Day One Biopharmaceuticals Inc   (NASDAQ: DAWN)
Other Ticker:  
 

Day One Biopharmaceuticals Inc

DAWN's Fundamental analysis



Looking into Day One Biopharmaceuticals Inc growth rates, revenue grew in III. Quarter 2024 from the same quarter a year ago. Ranking at No. 11

Major Pharmaceutical Preparations industry recorded growth of revenues by 9.75 %



• More on DAWN's Growth


Day One Biopharmaceuticals Inc
realized a net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 6.43 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 11.46.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.15.


• More on DAWN's Valuation
 
 Total Debt (Millions $) -
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 2,080,673
 Net Income/Employee (TTM) $ -2,393,408
 Receivable Turnover (TTM) 22.87
 Tangible Book Value (Per Share $) 5.56

Day One Biopharmaceuticals Inc
realized net loss in trailing twelve months.

Company is currently trading with Price to Cash flow multiple of 6.43 in trailing twelve-month period.
Company
-
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 11.46.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.15.

Day One Biopharmaceuticals Inc Price to Book Ratio is at 2.1 lower than Industry Avg. of 88.62. and higher than S&P 500 Avg. of 0.01

• More on DAWN's Valuation

•  Market Capitalization (Millions $) 1,168
•  Shares Outstanding (Millions) 97
•  Employees 49
•  Revenues (TTM) (Millions $) 102
•  Net Income (TTM) (Millions $) -117
•  Cash Flow (TTM) (Millions $) 182
•  Capital Exp. (TTM) (Millions $) -18
•  Total Debt (Millions $) -
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 2,080,673
•  Net Income/Employee(TTM) $ -2,393,408
•  Receivable Turnover Ratio (TTM) 22.87
•  Tangible Book Value (Per Share $) 5.56

•  Market Capitalization (Millions $) 1,168
•  Shares Outstanding (Millions) 97
•  Employees 49
•  Revenues (TTM) (Millions $) 102
•  Net Income (TTM) (Millions $) -117
•  Cash Flow (TTM) (Millions $) 182
•  Capital Exp. (TTM) (Millions $) -18


    DAWN's Profitability Comparisons
Day One Biopharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 31.61 %.

Day One Biopharmaceuticals Inc net profit margin of 78.06 % is currently ranking no. 7 in Major Pharmaceutical Preparations industry, ranking no. 12 in Healthcare sector and number 75 in S&P 500.


Profitability by Segment
Total 78.06 %



  Ratio
•   Capital Ratio (MRQ) 14.62
•  Total Debt to Equity (MRQ) -
•  Tangible Leverage Ratio (MRQ) 0.08
•  Asset Turnover Ratio (TTM) 0.24
•  Inventory Turnover Ratio (TTM) -



Day One Biopharmaceuticals Inc achieved increase in profitability, due to increase in demand and cost control. Operating Margin grew in III. Quarter 2024 to 31.61 %.

Day One Biopharmaceuticals Inc net profit margin of 78.06 % is currently ranking no. 7 in Major Pharmaceutical Preparations industry, ranking no. 12 in Healthcare sector and number 75 in S&P 500.

• More on DAWN's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com